Loading
A phase 2 trial of Obinutuzumab, Glofitamab, Pirtobrutinib and clonoSEQ in Mantle cell lymphoma, run by University of California, San Francisco, now recruiting.
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT06252675 by University of California, San Francisco, with 30 participants planned, started 2024-06-11 and due to reach its primary completion in 2028-07-31. Interventions recorded: Obinutuzumab, Glofitamab, Pirtobrutinib, Tumor Imaging, Biospecimen Collection, ClonoSeq Assay, Bone Marrow Biopsy. Conditions recorded: Mantle Cell Lymphoma.
Linked to the drug clonoSEQ because the registry names it among its interventions and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glofitamab, Obinutuzumab, Mantle cell lymphoma and the tag pipeline.
Shares clonoSEQ and the tag pipeline.
Shares Pirtobrutinib, Mantle cell lymphoma and the tag pipeline.
Shares Glofitamab, Obinutuzumab and the tag pipeline.
Shares Glofitamab, Obinutuzumab and the tag pipeline.
Shares clonoSEQ and the tag pipeline.
Shares Glofitamab, Obinutuzumab and the tag pipeline.
Shares Pirtobrutinib and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/